Founded in 2014 and headquartered in Vienna, Austria, enGenes has built a portfolio of platforms that consistently deliver titers, solubility, and secretion performance beyond the reach of conventional E. coli systems. 

The partnership addresses the disconnect between initial expression system development and GMP manufacturing, which costs early-stage programs three to six months in development time, states NorthX Biologics. The pathway helps biopharma developers reach clinical milestones faster, reducing scale-up risk and improving process predictability, they state. 

Making manufacturability part of the conversation from the start

“The biotech companies we work with are under real pressure. Less capital, faster timelines, higher expectations from investors. Still, programs arrive at GMP with expression systems that were never built to scale, and fixing that can take months. This partnership exists to change that by making manufacturability part of the conversation from the start. In the current environment, that kind of predictability determines whether a program moves forward at all,” says Janet Hoogstraate, CEO, NorthX Biologics.

The partnership

The partnership combines enGenes’ enGenes-eXpress platform with NorthX Biologics’ capabilities in process development, analytics, scale-up, and GMP manufacturing.

Under the partnership terms, enGenes performs high-throughput expression optimization, including host/vector screening, soluble expression enhancement, extracellular secretion strategies, and antibiotic marker-free production. The resulting expression system and full technical data package are transferred directly into NorthX Biologics’ pre-validated development and GMP manufacturing workflow. This creates a continuous pathway from genetic construct to clinical-grade material.